Introduction. The presence of diabetes mellitus in patients with acute infarction significantly worsens short- and long-term prognosis, but the features of the course of the infarction in this category of patients have not been fully studied.Objective. To compare clinical, functional and structural myocardial characteristics of patients with acute ST-segment elevation myocardial infarction with and without diabetes mellitus.Materials and methods. The study included 91 patients with revascularized ST-segment elevation myocardial infarction (41 patients with diabetes mellitus). All patients underwent cardiac MRI with contrast, including myocardial T1 mapping, tissue analysis of left ventricular myocardium with determination of infarct zone, heterogeneous zone, edema zone, pre- and post-contrast T1 values, extracellular volume values of healthy myocardium and infarct zone.Results. The presence of diabetes in patients with AMI was associated with increased EDV LV: 153 ± 38 and 181 ± 58 ml (p = 0.007), increased ESV LV: 76 ml [54–93] and 87 ml [71–122] (p = 0.035). Infarct size was significantly larger in patients with diabetes than in those without diabetes: 37 ± 15 g (95% CI: 33–41) and 47 ± 21 g (95% CI: 40–53), p = 0.017. Patients with acute infarction and diabetes mellitus had higher extracellular volume values in both healthy myocardium: 24% [22–27] and 28% [24–30], p = 0.002, and in the infarct zone: 48% [40–58] and 58% [50–61], p = 0.016.Conclusions. In patients with ST-segment elevation myocardial infarction with diabetes mellitus, the infarct size, the edema area, and the value of the extracellular volume fraction both in the infarct area and in the preserved myocardium were larger than in patients without diabetes, which may underlie the development of myocardial dysfunction and further progression of heart failure.
Takotsubo syndrome (TS) is a transient stress-induced left ventricular dysfunction that may clinically mimic acute myocardial infarction (MI). Its occurrence after percutaneous coronary intervention is rare, and it may be misinterpreted as a procedural complication, including type 4a MI. We describe a 77-year-old woman with stable coronary artery disease who developed apical TS shortly after elective stenting of the left anterior descending artery. Postprocedural chest pain and electrocardiographic changes raised suspicion of acute MI. However, coronary angiography demonstrated patent stent implantation without evidence of acute thrombosis. Cardiac magnetic resonance imaging confirmed apical ballooning with myocardial edema in the absence of necrosis, consistent with TS. TS after percutaneous coronary intervention is an uncommon but important diagnostic consideration. Differentiation from periprocedural MI requires integration of clinical findings, coronary imaging, and cardiac magnetic resonance imaging. Recognition of this condition is essential to avoid unnecessary escalation of antithrombotic therapy and to guide appropriate management.
It is known that the risk of thrombotic events in patients with acute coronary syndrome (ACS) is highest in the first year after the event. Regardless of the treatment tactics, dual antiplatelet therapy (DAPT) is prescribed for a year after. DAPT significantly prevents thrombotic events, primarily recurrent myocardial infarction. At the same time, the bleeding risk naturally increases. In recent years, convincing data have been obtained that the transition from DAPT to ticagrelor monotherapy 1-3 months after the event leads to a significant reduction in the bleeding risk without increasing the rate of thrombotic events compared to 12-month DAPT. The review analyzes data from randomized clinical trials comparing DAPT and ticagrelor monotherapy in patients with ACS and presents the provisions of Russian and international clinical guidelines for the treatment of ACS regarding ticagrelor monotherapy. The review aim is to rationale the advantage of ticagrelor monotherapy compared to standard DAPT in patients with ACS and percutaneous coronary intervention using a detailed analysis of randomized controlled trials and meta-analyses. The practical part presents the relevant sections of the clinical guidelines.